{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:04:55Z","timestamp":1761102295259},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s11899-017-0422-x","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T06:49:19Z","timestamp":1508827759000},"page":"592-597","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN"],"prefix":"10.1007","volume":"12","author":[{"given":"Naveen","family":"Pemmaraju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audun","family":"Utengen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"key":"422_CR1","first-page":"220","volume":"14","author":"N Pemmaraju","year":"2016","unstructured":"Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14:220\u20132.","journal-title":"Clin Adv Hematol Oncol"},{"key":"422_CR2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","volume":"98","author":"L Pagano","year":"2013","unstructured":"Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239\u201346.","journal-title":"Haematologica"},{"key":"422_CR3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.bmt.1704215","volume":"32","author":"P Reimer","year":"2003","unstructured":"Reimer P, Rudiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32:637\u201346.","journal-title":"Bone Marrow Transplant"},{"key":"422_CR4","doi-asserted-by":"publisher","unstructured":"Menezes J, Acquadro F, Wiseman M, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 2013. 2014;28(4):823\u20139. https:\/\/doi.org\/10.1038\/leu.2013.283 .","DOI":"10.1038\/leu.2013.283"},{"key":"422_CR5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"422_CR6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.24258","volume":"91","author":"U Deotare","year":"2016","unstructured":"Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol. 2016;91:283\u20136.","journal-title":"Am J Hematol"},{"key":"422_CR7","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23567","volume":"88","author":"K Alayed","year":"2013","unstructured":"Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88:1055\u201361.","journal-title":"Am J Hematol"},{"key":"422_CR8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"422_CR9","doi-asserted-by":"crossref","first-page":"10174","DOI":"10.18632\/oncotarget.7101","volume":"7","author":"L Martin-Martin","year":"2016","unstructured":"Martin-Martin L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7:10174\u201381.","journal-title":"Oncotarget"},{"key":"422_CR10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.14146","volume":"174","author":"L Pagano","year":"2016","unstructured":"Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174:188\u2013202.","journal-title":"Br J Haematol"},{"key":"422_CR11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","volume":"121","author":"D Roos-Weil","year":"2013","unstructured":"Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440\u20136.","journal-title":"Blood"},{"key":"422_CR12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.bbmt.2013.01.027","volume":"19","author":"MA Kharfan-Dabaja","year":"2013","unstructured":"Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1006\u201312.","journal-title":"Biol Blood Marrow Transplant"},{"key":"422_CR13","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","volume":"125","author":"T Aoki","year":"2015","unstructured":"Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559\u201362.","journal-title":"Blood"},{"key":"422_CR14","unstructured":"Pemmaraju N, Thomas D, Kantarjian HM, et al. Analysis of outcomes of patients with blastic plasmacytoid dendritic cell neoplasm. ASH Annual Meeting Abstracts 2012;120:3554."},{"key":"422_CR15","doi-asserted-by":"publisher","unstructured":"Frankel A. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. ASCO Annual Meeting 2013; J Clin Oncol (Meeting Abstracts) 2014;17;124(3):385\u201392. https:\/\/doi.org\/10.1182\/blood-2014-04-566737 .","DOI":"10.1182\/blood-2014-04-566737"},{"key":"422_CR16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","volume":"7","author":"J Montero","year":"2017","unstructured":"Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer discovery. 2017;7:156\u201364.","journal-title":"Cancer discovery"},{"key":"422_CR17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","volume":"30","author":"M Ceribelli","year":"2016","unstructured":"Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30:764\u201378.","journal-title":"Cancer Cell"},{"key":"422_CR18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","volume":"2","author":"U Testa","year":"2014","unstructured":"Testa U, Pelosi E, Frankel ACD. 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomarker research. 2014;2:4.","journal-title":"Biomarker research"},{"key":"422_CR19","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood.V122.21.2502.2502","volume":"122","author":"MR Sapienza","year":"2013","unstructured":"Sapienza MR, Fabio F, Claudio A, et al. Molecular profiling of blastic plasmacytoid dendritic CELL neoplasm reveals a unique pattern and suggests selective sensitivity to NF-KB pathway inhibition. Blood. 2013;122:2502.","journal-title":"Blood"},{"key":"422_CR20","doi-asserted-by":"publisher","unstructured":"Pemmaraju N, Gupta V, Thompson MA, Lane AA.Social media and internet resources for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Curr Hematol Malig Rep 2016;11(6):462\u2013467. https:\/\/doi.org\/10.1007\/s11899-016-0340-3 .","DOI":"10.1007\/s11899-016-0340-3"},{"key":"422_CR21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11899-015-0287-9","volume":"10","author":"N Pemmaraju","year":"2015","unstructured":"Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)\u2014focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015;10:413\u201320.","journal-title":"Curr Hematol Malig Rep"},{"key":"422_CR22","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1200\/jco.2015.33.15_suppl.6520","volume":"33","author":"MS Katz","year":"2015","unstructured":"Katz MS, Utengen A, Anderson PF, Thompson MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol. 2015;33; suppl abstr:6520.","journal-title":"J Clin Oncol"},{"key":"422_CR23","doi-asserted-by":"crossref","unstructured":"Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)-focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015;","DOI":"10.1007\/s11899-015-0287-9"},{"key":"422_CR24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s11899-016-0341-2","volume":"11","author":"N Pemmaraju","year":"2016","unstructured":"Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN): analysis of advanced metrics from the first year of a new twitter community: #MPNSM. Curr Hematol Malig Rep. 2016;11:456\u201361.","journal-title":"Curr Hematol Malig Rep"},{"key":"422_CR25","doi-asserted-by":"publisher","unstructured":"Perales MA, Drake EK, Pemmaraju N, Wood WA. Social media and the adolescent and young adult (AYA) patient with cancer. Curr Hematol Malig Rep 2016;11(6):449\u2013455. https:\/\/doi.org\/10.1007\/s11899-016-0313-6 .","DOI":"10.1007\/s11899-016-0313-6"},{"key":"422_CR26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/jamaoncol.2015.3960","volume":"2","author":"MS Katz","year":"2016","unstructured":"Katz MS, Utengen A, Anderson PF, et al. Disease-specific hashtags for online communication about cancer care. JAMA Oncol. 2016;2:392\u20134.","journal-title":"JAMA Oncol"},{"key":"422_CR27","doi-asserted-by":"crossref","unstructured":"Pemmaraju Nea. Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood (ASH abstract #4245, Dec 2016)2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.7006"},{"key":"422_CR28","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1200\/JOP.2017.021634","volume":"13","author":"N Pemmaraju","year":"2017","unstructured":"Pemmaraju N, Thompson MA, Mesa RA, Desai T. Analysis of the use and impact of twitter during American Society of Clinical Oncology annual meetings from 2011 to 2016: focus on advanced metrics and user trends. J oncol prac \/ Am Soc Clin Oncol. 2017;13:e623\u2013e31.","journal-title":"J oncol prac \/ Am Soc Clin Oncol"},{"key":"422_CR29","doi-asserted-by":"publisher","unstructured":"Pemmaraju N MR, Majhail NS, Thompson MA. The use and impact of Twitter at medical conferences: best practices and Twitter etiquette. Semin Hematol 2017; https:\/\/doi.org\/10.1053\/j.seminhematol.2017.08.003 .","DOI":"10.1053\/j.seminhematol.2017.08.003"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-017-0422-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0422-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0422-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T04:12:34Z","timestamp":1659672754000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-017-0422-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1007\/s11899-017-0422-x","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,24]]}}}